AI Regulatory Affairs Agents for Medical Device Teams: What They Are, How They Work and Where They Fit 

An AI regulatory affairs agent is a specialised AI system that carries out defined regulatory and quality compliance tasks for medical devices. It can break a regulatory question into several steps, search relevant sources, apply task-specific logic and produce an evidence-backed output for review. 

Medical device teams can use these agents for classification, pathway identification, regulatory research, document drafting, submission-readiness checks and quality management system gap analysis. 

Their value depends on the quality of the regulatory logic, source material, traceability and review process. The medical device manufacturer remains responsible for regulatory decisions, evidence and documentation. 

This article explains how AI regulatory affairs agents differ from generic chatbots and conventional software, why medical device teams are adopting them, which workflows they can support, how to assess their credibility, where human oversight remains essential, and how they fit within MedTech companies and regulatory consultancies. 

What is an AI regulatory affairs agent? 

An AI regulatory affairs agent performs specialised regulatory work through a sequence of connected actions. 

When a user submits a question, the agent can determine what information is needed, divide the task into stages, search relevant databases or documents and combine the findings into a structured output. 

A specialised regulatory agent adds regulatory knowledge, task-specific workflows and access to appropriate reference material. 

For example, when assessing whether a device fits an existing US product code, the analysis to consider: 

• the device’s intended use; 

• its technological characteristics; 

• differences from existing devices; 

• whether those differences introduce new questions of safety or effectiveness; 

• whether existing regulatory controls can address those questions. 

A general AI assistant may identify broad similarities between devices. A regulatory agent should assess whether those similarities are relevant to the regulatory decision. 

The term “agent” does not guarantee reliability 

“Agent” describes how a system performs work. It does not confirm that its conclusions are correct. 

A regulatory agent can still produce an incomplete or unsuitable output when: 

• The system does not check if the input is sufficiently specified; 

• the source collection is incomplete or outdated; 

• the workflow does not reflect the applicable regulatory logic; 

• the system fails to recognise an unusual device characteristic; 

• the system fails to provide its underlying reasoning for users to review the analysis. 

Teams should assess the system’s reasoning, evidence and controls rather than rely on the product label. 

Why medical device teams are exploring regulatory AI 

Manual regulatory workflows are hard to scale-up due to compounding complexity 

Medical device regulation involves a connected set of decisions, requirements and evidence. 

Before development progresses too far, a manufacturer needs to determine: 

• whether the product is a medical device; 

• the relevant device classification; 

• the likely regulatory pathway; 

• applicable regulations, guidance and standards; 

• the evidence required to support safety and performance; 

• the documentation and quality-system processes needed throughout development. 

Every design iteration, risk management update, or post-market surveillance finding triggers a cascade that impacts several documents and new supporting evidence. 

A revised intended purpose may alter classification. A newly identified hazard may require an additional risk control. That control may create a new design requirement, verification activity, usability consideration or clinical-evidence need. 

Correcting one gap can therefore require updates across several documents and new supporting evidence. 

Left unmanaged, this compounding administrative burden creates severe operational bottlenecks. As compliance requirements scale faster than internal teams can hire, manual document management leads to prolonged submission cycles, delayed market entry, and heightened risk of non-compliance errors. 

Specialist capacity is limited 

Regulatory professionals and consultants work across large volumes of material while supporting several products, markets and internal stakeholders. 

Manual research, document comparison and consistency review take time that experts could spend on interpretation, risk assessment and strategic decisions. 

AI regulatory affairs agents can support teams by: 

• accelerating regulatory research; 

• structuring early pathway analysis; 

• preparing first drafts; 

• reviewing large document sets; 

• identifying possible gaps earlier; 

• supporting comparison across several scenarios. 

These benefits depend on the quality of the system and the review process around it. 

Teams need regulatory clarity earlier 

Regulatory strategy affects product claims, development choices, evidence plans, budgets and timelines. 

Starting regulatory analysis after the device has already been built can expose requirements that would have been easier to address during concept and design. 

An AI regulatory affairs agent can help teams examine regulatory implications earlier, before product decisions become difficult or expensive to change. 

Why general-purpose AI has limits in MedTech regulatory work 

General-purpose AI can support document summarisation, restructuring and language improvement. These tasks may not require a specialised regulatory system. 

The limits become more significant when the tool is used to support a regulatory determination. 

Generic tools may not follow the required regulatory logic 

Regulatory analysis often depends on a defined sequence of questions. 

Consider two software devices that analyse the same type of medical image. One outlines an area for a clinician to inspect. Another interprets the image and recommends a diagnosis. 

The technologies may be related, but the clinical function, risk profile and evidence requirements differ. 

A regulatory analysis needs to consider: 

• intended use; 

• technological differences; 

• questions of safety or effectiveness; 

• risks created by those differences; 

• the controls needed to address them. 

Broad similarity is not enough to support a regulatory conclusion. 

Model memory is not a controlled regulatory source 

Although most large language model have encountered regulatory documents during training, they do not retain every requirement as an exact and current reference. 

A model can produce an answer that appears plausible while misstating a requirement, using outdated information or combining details from different sources. 

For regulatory work, the system should retrieve the relevant current document, identify the applicable passage and show how that information informed the conclusion. 

This is especially important when the task involves: 

• current regulations; 

• updated guidance; 

• jurisdiction-specific requirements; 

• standards; 

• product-code information; 

• approved-device data; 

• quality-system requirements. 

Regulatory output needs to be reviewable 

A team should be able to see: 

• which device information was considered; 

• which sources were used; 

• which regulatory tests or decision steps were applied; 

• how the conclusion was reached; 

• where uncertainty remains; 

• what requires human confirmation. 

Without this information, the team may need to repeat the analysis to verify the result. 

Where AI regulatory affairs agents can support medical device teams 

The strongest use cases are structured, evidence-intensive tasks that can be divided into clear regulatory steps. 

Medical device classification and pathway planning 

During the concept or early development stage, an agent may help organise and assess: 

• intended purpose or intended use; 

• device type and functionality; 

• risk classification; 

• relevant product codes; 

• comparable or predicate devices; 

• possible US submission pathways; 

• possible EU conformity-assessment implications; 

• applicable regulatory controls, guidance and standards. 

The output should include assumptions, unresolved questions and the basis for the proposed direction. 

It should be reviewed by a qualified person and should not be treated as a binding decision from a regulator or notified body. 

Supporting guide: AI Agent for Medical Device Classification and Regulatory Pathway Planning 

Regulatory research 

Regulatory teams often need to answer questions spread across regulations, guidance, databases and internal documentation. 

A research agent can: 

• retrieve applicable source material; 

• synthesise information from several documents; 

• compare regulatory positions; 

• identify requirements relevant to the device; 

• answer questions about project documentation; 

• preserve references for later verification. 

Its value comes from searching within a defined regulatory context and relating the findings to a device or task. 

Drafting technical and quality documentation 

Specialised agents can help create structured first drafts from information already established about the device. 

Examples include: 

• clinical evaluation plans; 

• risk management plans; 

• post-market surveillance plans; 

• quality management system procedures; 

A clinical evaluation plan depends on several upstream inputs, including: 

• device characteristics; 

• intended purpose; 

• clinical context; 

• state of the art; 

• risk analysis; 

• the evidence needed to support the device’s claims. 

A useful drafting workflow should build from those inputs rather than generate a generic template. 

The manufacturer must review and own the content. Proposed risk controls, evidence plans and procedures affect real development and operational activities. 

FDA submission readiness and gap analysis 

An AI agent may compare a developing submission with the requirements associated with the relevant FDA pathway. 

Potential checks include: 

• expected submission components; 

• consistency between intended use, indications, claims and supporting documents; 

• predicate or comparison logic; 

• evidence mapping; 

• missing information; 

• unresolved requirements; 

• inconsistencies across submission sections; 

• gaps within software, cybersecurity, usability, electrical-safety, biocompatibility, sterility or other relevant documentation. 

The review should begin with an appropriate pathway determination. A generic checklist is unlikely to reflect all device-specific requirements. 

A useful finding should explain: 

• what may be missing; 

• where the issue appears; 

• which requirement is relevant; 

• why the current content may be insufficient; 

• how the gap can be addressed; 

• what the reviewer should examine next. 

Supporting guide: AI Agent for FDA Submission Readiness: From Pathway Clarity to Gap Review 

MDR compliance and technical-documentation review 

For EU medical devices, agents may help review alignment across areas such as: 

• intended purpose; 

• classification; 

• general safety and performance requirements; 

• AI Act requirements; 

• applicable MDCG guidances; 

• technical documentation including consistency and traceability between evidence and claims, risk management, clinical evaluation, post-market surveillance; 

The review should distinguish between regulations, guidance, standards and internal documentation. 

A finding should show: 

• the source; 

• the relevant requirement or expectation; 

• the document or section under review; 

• the gap or inconsistency; 

• the reasoning behind the finding. 

Supporting guide: AI Agent for MDR Compliance: Classification, Technical Documentation and Traceable Review 

Quality management system review 

Regulatory agents can also support quality management system gap analysis. 

A review may examine whether: 

• required procedures are present; 

• a procedure addresses the applicable requirement; 

• records show that the organisation followed its own process; 

• responsibilities and approvals are defined; 

• connected documents remain consistent; 

• evidence is available for an internal or external audit. 

The system may identify two types of issue: 

1. the procedure does not adequately address the requirement; 

2. the organisation has not followed its own procedure. 

These findings require different corrective actions and should be reviewed in the context of the company’s processes and applicable requirements. 

AI agent, AI tool, software platform or regulatory consultant? 

The terms used for regulatory technology often overlap. The clearest distinction is the type of work each approach supports. 

Approach	What it generally does well	Main limitation	Appropriate use
General-purpose AI assistant	Summarisation, rewriting and basic document support	May lack controlled regulatory sources and task-specific logic	Low-risk supporting work with human verification
Regulatory database or search tool	Provides access to records and source documents	Interpretation and workflow execution remain with the user	Expert-led research
Point regulatory AI tool	Automates one defined activity	May not connect decisions across the lifecycle	High-volume, repeatable specialist tasks
Rules-based regulatory software	Applies predefined decision trees and workflows consistently	Can be rigid and dependent on correct user interpretation	Stable, well-defined processes
AI regulatory affairs agent	Executes multi-step tasks using regulatory context, tools and sources	Requires governance and expert oversight	Complex research, drafting and review workflows
Regulatory consultant	Provides judgement, accountability and strategic interpretation	Capacity, cost and turnaround may be limiting	Novel, ambiguous or commercially strategic decisions

A regulatory team may use several of these approaches together. 

General AI can support editing. Databases can provide source access. Specialised agents can accelerate analysis. Consultants and internal experts can address ambiguity, strategic choices and accountability. 

Teams should identify which parts of the workflow can be accelerated while preserving quality, traceability and regulatory control. 

What makes an AI regulatory affairs agent credible? 

A credible AI regulatory affairs agent combines current and controlled regulatory knowledge, task-specific logic, traceable reasoning and evidence, consistency across connected documentation, appropriate human oversight, and clear limits on what the system can determine. 

1. Controlled and current regulatory knowledge 

The system should retrieve relevant regulations, guidance, standards or database records rather than rely only on model memory. 

Teams should ask: 

• Which sources does the platform use? 

• How are they selected and maintained? 

• How quickly are updates incorporated? 

• Can users distinguish binding requirements from non-binding guidance? 

• Does the platform identify the version or publication date? 

2. Task-specific regulatory logic 

The workflow should reflect the regulatory task being performed. 

Classification, predicate analysis, clinical-evidence planning and quality-system review require different inputs and reasoning steps. 

Teams should ask the provider to explain: 

• which decision steps the agent follows; 

• which inputs are required; 

• how it handles missing information; 

• when it flags uncertainty; 

• how the workflow has been tested. 

3. Visible reasoning and evidence 

Users should be able to trace: 

• the input used; 

• the steps performed; 

• the relevant source; 

• the conclusion; 

• the rationale; 

• any missing or uncertain information. 

When the system flags a gap, it should indicate where the issue appears and which requirement supports the finding. 

4. Consistency across connected documents 

Regulatory documents should be reviewed in context. 

A claim in one document may need to align with: 

• intended purpose; 

• risk management; 

• verification evidence; 

• clinical evaluation; 

• labelling; 

• post-market plans. 

The agent should identify conflicts across the document set or state when its review is limited to one file. 

5. Human review and accountability 

Human approval is required at material decision points. 

The system should not imply that: 

• its output is regulator-approved; 

• responsibility can be delegated to the software; 

• every recommendation fits the clinical workflow; 

• expert review is optional. 

The manufacturer remains responsible for the regulatory decisions and documentation. 

6. Clear limitations 

A credible platform should identify what it cannot determine. 

Examples include: 

• missing device information; 

• novel technology without adequate comparators; 

• conflicting source material; 

• strategic choices involving risk appetite, investment or commercial positioning; 

• clinical questions requiring specialist input; 

• organisation-specific procedures the agent cannot observe. 

Clear limitations help teams decide when further expertise or regulator engagement is needed. 

Where do AI agents fit within the regulatory team? 

AI agents work best as analytical and productivity tools within a controlled regulatory process. 

They do not replace: 

• the manufacturer’s legal and regulatory responsibility; 

• the regulatory, clinical, engineering or quality professional’s judgement; 

• regulator or notified-body feedback; 

• document-control procedures; 

• strategic business decisions. 

Startups and early-stage MedTech companies 

Startups can use agents to structure regulatory questions earlier, explore plausible pathways and understand which requirements may affect development. 

Useful applications include: 

• early classification analysis; 

• pathway exploration; 

• requirements research; 

• scenario comparison; 

• document planning; 

• first-draft preparation. 

Established MedTech regulatory teams 

Internal teams can use agents to: 

• accelerate regulatory research; 

• prepare structured first drafts; 

• review technical and quality documentation; 

• identify gaps, inconsistencies and missing information across document sets; 

• support submission-readiness and audit preparation; 

• compare regulatory scenarios without adding to manual workload. 

The benefit is both additional capacity and more systematic regulatory work. Complex, interconnected requirements can make gaps or inconsistencies difficult to spot until they create significant rework. AI agents can help teams identify these issues earlier and review information more consistently, while regulatory experts focus on resolving ambiguity, assessing risk and advising product teams. 

Regulatory consultants 

Consultants can use agents to: 

• analyse more scenarios; 

• accelerate research; 

• review larger document sets; 

• identify gaps earlier; 

• prepare more comprehensive recommendations. 

The consultant still provides strategic interpretation. 

For example, a company may need to choose between a narrower initial claim that supports an earlier route to market and a broader claim that requires more evidence. 

An agent can analyse the regulatory implications of each scenario. The consultant integrates that into a borader advice on which route best fits the company’s strategy, resources and risk tolerance. 

When should a team use an AI regulatory affairs agent? 

The best time to begin is when the product concept is defined well enough to support meaningful regulatory analysis and before major development decisions become difficult to reverse. 

An agent is particularly relevant when a team needs: 

• early classification or pathway clarity; 

• faster retrieval of applicable requirements; 

• structured comparison of regulatory scenarios; 

• first drafts of evidence-based documents; 

• repeated review of developing submission materials; 

• traceability across a large document set; 

• QMS procedure or record gap analysis; 

• additional capacity for an overloaded regulatory team. 

A specialised agent may be unnecessary for simple editing, summarisation or administrative work that does not require regulatory interpretation. 

How Guideways supports medical device regulatory affairs 

Guideways uses four specialised agents across connected stages of the medical device regulatory lifecycle. 

Sherpa: regulatory strategy and requirements 

Sherpa supports: 

• classification; 

• predicate research; 

• pathway planning; 

• relevant guidance; 

• standards; 

• regulatory controls. 

It uses the device description, intended use / purpose and indications for use to establish a structured regulatory direction. 

Drafter: structured first drafts 

Drafter uses device and regulatory information already available in the platform to create first drafts of technical and quality documents. 

Examples include: 

• clinical evaluation plan; 

• risk management plan; 

• post-market surveillance plan; 

• quality management system procedures; 

• supporting technical-document sections. 

These outputs require review and approval by the responsible team. 

Reviewer: gap analysis and consistency review 

Reviewer analyses technical file submissions, quality systems and deelopment documentation to identify: 

• missing content; 

• inconsistencies; 

• weak rationales; 

• unmet requirements; 

• gaps across connected documents. 

Researcher: regulatory research 

Researcher answers questions using regulatory and project context. 

It supports users in identifying and interpreting relevant evidence from regulatory sources and project documentation. 

How the Guideways agents work together 

The agents share project and regulatory context. 

Drafter can use information and regulatory analysis established through Sherpa. A clinical evaluation plan, for example, can begin with the device description, pathway analysis and identified requirements already recorded in the platform. 

Researcher and Reviewer can also work with the regulatory sources and project documentation available within the same context. 

This continuity can reduce contradictions between early strategy, document preparation and later review. The team remains responsible for confirming the information and approving the outputs. 

Questions to ask before adopting an AI regulatory affairs agent 

Before selecting a platform, ask: 

1. Which regulatory tasks can the system perform? 

2. Which jurisdictions, pathways and device types does it cover? 

3. Which sources does it retrieve, and how are they updated? 

4. Can users inspect the reasoning and source behind each material conclusion? 

5. How does it distinguish regulations, guidance, standards and internal documents? 

6. Can it identify inconsistencies across multiple documents? 

7. How does it handle missing or conflicting information? 

8. Where does the workflow enable human review? 

9. How are sensitive product and quality-system data protected? 

10. Can the organisation test the system on a real device scenario before wider adoption? 

Conclusion 

AI regulatory affairs agents can support research, pathway analysis, drafting and document review across the medical device lifecycle. 

Their value depends on five factors: 

• regulatory logic suited to the task; 

• controlled and current sources; 

• traceable reasoning; 

• connected project context; 

• qualified human review. 

Teams should assess whether the system produces work that regulatory professionals can inspect, challenge and approve. 

Used within a controlled process, these agents increase regulatory capacity while keeping judgement and accountability with the people responsible for the device. 

Test an AI regulatory affairs agent on a device scenario 

See how Guideways applies regulatory logic, source material and project context to classification, pathway planning, document drafting or submission review. 

Book a demo.